Herbert Eradat1. 1. David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA. HEradat@mednet.ucla.edu.
Abstract
PURPOSE OF THIS REVIEW: This review summarizes the role of BCL-2 in the pathogenesis of CLL, and the clinical data evaluating safety and efficacy of venetoclax, in treatment of patients with CLL, in the context of other available targeted agents. RECENT FINDINGS: Venetoclax, alone or in combination with other targeted agents results in high rate of durable responses and undetectable measurable residual disease. Venetoclax maintains activity across all clinical and biologic subgroups, including those with high risk disease, including CLL with chromosome 17p deletion. TLS risk can be mitigated with risk stratification and five-week administration ramp-up schedule. Venetoclax, a novel, orally bioavailable inhibitor of BCL-2 has demonstrated substantial clinical activity in the treatment of CLL. In combination with other targeted agents it can induce high disease response rates and potentially lead to MRD-negative durable remissions.
PURPOSE OF THIS REVIEW: This review summarizes the role of BCL-2 in the pathogenesis of CLL, and the clinical data evaluating safety and efficacy of venetoclax, in treatment of patients with CLL, in the context of other available targeted agents. RECENT FINDINGS:Venetoclax, alone or in combination with other targeted agents results in high rate of durable responses and undetectable measurable residual disease. Venetoclax maintains activity across all clinical and biologic subgroups, including those with high risk disease, including CLL with chromosome 17p deletion. TLS risk can be mitigated with risk stratification and five-week administration ramp-up schedule. Venetoclax, a novel, orally bioavailable inhibitor of BCL-2 has demonstrated substantial clinical activity in the treatment of CLL. In combination with other targeted agents it can induce high disease response rates and potentially lead to MRD-negative durable remissions.
Authors: Paolo Strati; Michael J Keating; Susan M O'Brien; Jan Burger; Alessandra Ferrajoli; Nitin Jain; Francesco Paolo Tambaro; Zeev Estrov; Jeffrey Jorgensen; Pramoda Challagundla; Stefan H Faderl; William G Wierda Journal: Blood Date: 2014-04-04 Impact factor: 22.113
Authors: Mary Ann Anderson; Constantine Tam; Thomas E Lew; Surender Juneja; Manu Juneja; David Westerman; Meaghan Wall; Stephen Lade; Alexandra Gorelik; David C S Huang; John F Seymour; Andrew W Roberts Journal: Blood Date: 2017-05-04 Impact factor: 22.113
Authors: A Migliazza; F Bosch; H Komatsu; E Cayanis; S Martinotti; E Toniato; E Guccione; X Qu; M Chien; V V Murty; G Gaidano; G Inghirami; P Zhang; S Fischer; S M Kalachikov; J Russo; I Edelman; A Efstratiadis; R Dalla-Favera Journal: Blood Date: 2001-04-01 Impact factor: 22.113
Authors: Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2005-09-15 Impact factor: 11.205
Authors: Xavier C Badoux; Michael J Keating; Xuemei Wang; Susan M O'Brien; Alessandra Ferrajoli; Stefan Faderl; Jan Burger; Charles Koller; Susan Lerner; Hagop Kantarjian; William G Wierda Journal: Blood Date: 2011-01-18 Impact factor: 22.113
Authors: Mary Ann Anderson; Jing Deng; John F Seymour; Constantine Tam; Su Young Kim; Joshua Fein; Lijian Yu; Jennifer R Brown; David Westerman; Eric G Si; Ian J Majewski; David Segal; Sari L Heitner Enschede; David C S Huang; Matthew S Davids; Anthony Letai; Andrew W Roberts Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: Francis R LeBlanc; Jennifer M Pearson; Su-Fern Tan; HeeJin Cheon; Jeffrey C Xing; Wendy Dunton; David J Feith; Thomas P Loughran Journal: Br J Haematol Date: 2020-03-02 Impact factor: 6.998